Silverarc Capital Management, LLC Apellis Pharmaceuticals, Inc. Transaction History

Silverarc Capital Management, LLC

  • $402 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$37.14 - $64.82 $371,400 - $648,199
10,000 New
10,000 $598,000
Q2 2022

Jul 25, 2022
BUY
$35.07 - $59.21 $856,654 - $1.45 Million
24,427 Added 23.18%
129,795 $5.87 Million
Q1 2022

May 13, 2022
BUY
$35.46 - $54.12 $3.74 Million - $5.7 Million
105,368 New
105,368 $5.35 Million
Q3 2021

Nov 15, 2021
SELL
$31.4 - $69.84 $220,082 - $489,508
-7,009 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$40.9 - $64.9 $286,668 - $454,884
7,009 New
7,009 $443,000

Others Institutions Holding APLS

# of Institutions
308
Shares Held
115M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email